LXH254 is primarily used in the field of oncology research as a selective inhibitor of the RAF kinase family, particularly targeting BRAF and CRAF proteins. Its application is significant in studying and developing treatments for cancers driven by mutations in the MAPK signaling pathway, such as melanoma, colorectal cancer, and non-small cell lung cancer. Researchers utilize LXH254 to explore its potential in blocking tumor growth and proliferation by inhibiting the aberrant signaling caused by these mutations. Additionally, it is being investigated in combination therapies to enhance efficacy and overcome resistance to existing treatments. Its role in preclinical studies helps in understanding the molecular mechanisms of RAF-dependent cancers and in identifying new therapeutic strategies.